Ajax Therapeutics
Tracked across 5 events · 50 articles · First seen May 01, 2026 · Last active Sep 22, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Ajax Therapeutics is the licensee and primary beneficiary, gaining exclusive worldwide rights to a new SGK1 inhibitor scaffold, expanding its pipeline into neurodegenerative diseases and potentially increasing its market value.
Sep 03, 2026 · 6 articles
Business
Lexeo Therapeutics, Inc. (LXEO) announced a series of strategic transactions to expand its presence in Friedreich ataxia (FA), including a definitive agreement to acquire privately held clinical-stage company Ajax Therapeutics, Inc. The acquisition adds multiple…
Impact: Mantle is the private clinical-stage target being acquired for up to $21.3 million, contributing four FA assets including LX3010. The acquisition provides its shareholders with upfront cash and equity plus milestone payments.
Sep 22, 2026 · 6 articles
Business
Impact: Ajax Therapeutics was recently purchased by Eli Lilly and Company, highlighting the trend of mid-size acquisitions in the biotech sector.
May 01, 2026 · 6 articles
Business
Alkermes (Nasdaq: ALKS) announced the appointment of Anne C. Whitaker as a new independent director to its Board of Directors. The appointment was announced on Wednesday, September 16, 2026, according to a company press release.…
Impact: Aerami is Whitaker's most recent CEO role, cited as part of her background; no direct impact from the event.
Sep 16, 2026 · 7 articles
Business
Impact: Ajax Therapeutics was acquired by Eli Lilly earlier in 2026, focusing on blood cancer.
Jul 16, 2026 · 25 articles
55
Lexeo Therapeutics signed option agreement Ajax TherapeuticsLexeo Acquires Mantle...
ERGEN INTELLIGENCE
Track Ajax Therapeutics live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard